市場調査レポート

商品コード

1722414

潰瘍性大腸炎市場レポート：タイプ別、疾患タイプ別、分子タイプ別、薬剤タイプ別、投与経路別、流通チャネル別、地域別、2025年～2033年

Ulcerative Colitis Market Report by Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033

出版日: 2025年05月01日
発行: IMARC
ページ情報: 英文 134 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF & Excel (Single User License)

USD 2,999 438,093円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDFおよびExcelの印刷は一度のみ可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (5 User License)

USD 3,999 584,173円

レポートPDFおよびExcelを同一企業内の5名様までがご利用頂けるライセンスです。PDFおよびExcelの印刷は可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Corporate License)

USD 4,999 730,253円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等の編集は可能ですが、事前にIMARC Services Private Limited社の許可が必要です。PDFおよびExcelの印刷回数に制限はありません。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.08円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の潰瘍性大腸炎の市場規模は2024年に82億米ドルに達しました。今後、IMARC Groupは、同市場が2033年までに125億米ドルに達し、2025～2033年の成長率（CAGR）は4.82％に達すると予測しています。同市場は、有病率の上昇、治療法の進歩、政府の支援政策などにより成長を遂げています。さらに、先進国や新興国市場における革新的な治療法に対する世界の意識の高まりが、市場にさらなる付加価値をもたらしています。

潰瘍性大腸炎の市場分析：

主な市場促進要因：潰瘍性大腸炎の世界の患者数の急増、炎症性腸疾患の存在に対する認知度が、患者の間で革新的な治療法や診断法に対する需要を刺激しています。さらに、技術の進歩、生物製剤の拡大、新しい治療法の発明が市場開拓を強化しています。先進国や新興諸国におけるヘルスケアへの支出の増加も市場拡大を促進します。

主な市場動向：潰瘍性大腸炎の治療において、遺伝的、環境的、表現型の特徴に基づいてカスタマイズされた治療法を重視する個別化医療の傾向が強まっています。さらに、重症例管理のための生物製剤やバイオシミラーの採用拡大が、この市場における製薬業界の方向性に大きな影響を与えています。

地理的動向：北米は、高度なヘルスケア施設、高い医療費、確立された製薬企業により、潰瘍性大腸炎の市場をリードしています。しかし、アジア太平洋地域は、医療施設の増加、患者の意識の向上、中国やインドなどの医療ツーリズムの中心地であることから、大きな発展が見込まれています。

競合情勢：潰瘍性大腸炎の業界の主要市場プレイヤーには、アボット・ラボラトリーズ、AbbVie Inc.、AstraZeneca plc、Bristol-Myers Squibb Company、Eli Lilly and Company、F. Hoffmann-La Roche Ltd.、GlaxoSmithKline plc、Johnson &Johnson、Merck &Co.ファイザー、武田薬品工業、テバ・ファーマシューティカル・インダストリーズなどです。

課題と機会：同市場の主な課題は治療費の高さであり、特に生物学的製剤が関与している場合、低所得国においてアクセスの障壁となる可能性があります。もう一つの要因は、新薬の承認手続きに手間がかかり、時間がかかることで、新しい治療法の市場参入が遅れる可能性があります。課題の深刻さにもかかわらず、この課題はチャンスを生み出す基礎となり得る。費用対効果の高い治療法の開発と承認プロセスの合理化は、世界中の企業にとって有益なものとなり得る。

潰瘍性大腸炎の市場の動向：

潰瘍性大腸炎の有病率の増加

潰瘍性大腸炎の有病率の増加、炎症性腸疾患の存在に対する認知の広がりは、患者の間で革新的な治療法や診断法に対する需要を刺激しています。さらに、技術の進歩、生物製剤の拡大、新しい治療法の発明が市場開拓を強化しています。先進国や新興諸国におけるヘルスケアへの支出の増大も市場拡大を促進します。NATIONAL LIBRARY OF MEDICINEによると、潰瘍性大腸炎の年間罹患率は10万人あたり9～20人です。有病率は10万人あたり156～291人です。

治療の進歩

潰瘍性大腸炎の治療は、生物学的製剤や低分子医薬品の開発により大きく進歩しました。この進歩がもたらした前向きな精神は、市場関連でより有利な要因を生み出しています。一方では、診断技術の進歩や新たな標的治療アプローチの開発が、より効果的な治療法の開発による採用の増加により、市場にプラスの影響を与えています。例えば、ファイザー社は2023年、米国食品医薬品局（FDA）が、中等度から重度の活動性を有する成人のスフィンゴシン-1-リン酸（S1P）受容体モジュレーターであるVELSIPITY（TM）（エトラシモド）を1日1回経口投与で承認したと発表しました。

政府および規制当局の支援

政府の好意的な政策とヘルスケア支出の増加は、潰瘍性大腸炎の市場の成長に大きな影響を与えます。規制当局の承認により、効果的な新薬の迅速な市場参入が促進され、患者は先進的な治療オプションを利用できるようになります。さらに、いくつかの政府は研究開発への資金援助を強化し、製薬会社が潰瘍性大腸炎の革新的な治療法に投資することを奨励しており、これが市場の成長をさらに刺激しています。

北米
- 米国
- カナダ
アジア太平洋地域
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
中東・アフリカ
- 市場内訳：国別

第13章 SWOT分析

概要
強み
弱み
機会
脅威

第14章バリューチェーン分析

第15章ポーターのファイブフォース分析

概要
買い手の交渉力
供給企業の交渉力
競合の程度
新規参入業者の脅威
代替品の脅威

第16章価格分析

第17章競合情勢

市場構造
主要企業
主要企業のプロファイル
- Abbott Laboratories
- AbbVie Inc.
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co. Inc.
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.

図表

List of Figures

Figure 1: Global: Ulcerative Colitis Market: Major Drivers and Challenges
Figure 2: Global: Ulcerative Colitis Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Ulcerative Colitis Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 4: Global: Ulcerative Colitis Market: Breakup by Type (in %), 2024
Figure 5: Global: Ulcerative Colitis Market: Breakup by Disease Type (in %), 2024
Figure 6: Global: Ulcerative Colitis Market: Breakup by Molecule Type (in %), 2024
Figure 7: Global: Ulcerative Colitis Market: Breakup by Drug Type (in %), 2024
Figure 8: Global: Ulcerative Colitis Market: Breakup by Route of Administration (in %), 2024
Figure 9: Global: Ulcerative Colitis Market: Breakup by Distribution Channel (in %), 2024
Figure 10: Global: Ulcerative Colitis Market: Breakup by Region (in %), 2024
Figure 11: Global: Ulcerative Colitis (Mild UC) Market: Sales Value (in Million USD), 2019 & 2024
Figure 12: Global: Ulcerative Colitis (Mild UC) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 13: Global: Ulcerative Colitis (Moderate UC) Market: Sales Value (in Million USD), 2019 & 2024
Figure 14: Global: Ulcerative Colitis (Moderate UC) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 15: Global: Ulcerative Colitis (Severe UC) Market: Sales Value (in Million USD), 2019 & 2024
Figure 16: Global: Ulcerative Colitis (Severe UC) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 17: Global: Ulcerative Colitis (Ulcerative Proctitis) Market: Sales Value (in Million USD), 2019 & 2024
Figure 18: Global: Ulcerative Colitis (Ulcerative Proctitis) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 19: Global: Ulcerative Colitis (Proctosigmoiditis) Market: Sales Value (in Million USD), 2019 & 2024
Figure 20: Global: Ulcerative Colitis (Proctosigmoiditis) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 21: Global: Ulcerative Colitis (Left-sided Colitis) Market: Sales Value (in Million USD), 2019 & 2024
Figure 22: Global: Ulcerative Colitis (Left-sided Colitis) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 23: Global: Ulcerative Colitis (Pancolitis or Universal Colitis) Market: Sales Value (in Million USD), 2019 & 2024
Figure 24: Global: Ulcerative Colitis (Pancolitis or Universal Colitis) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 25: Global: Ulcerative Colitis (Fulminant Colitis) Market: Sales Value (in Million USD), 2019 & 2024
Figure 26: Global: Ulcerative Colitis (Fulminant Colitis) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 27: Global: Ulcerative Colitis (Small Molecules) Market: Sales Value (in Million USD), 2019 & 2024
Figure 28: Global: Ulcerative Colitis (Small Molecules) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 29: Global: Ulcerative Colitis (Biologics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 30: Global: Ulcerative Colitis (Biologics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 31: Global: Ulcerative Colitis (Anti-Inflammatory Drugs) Market: Sales Value (in Million USD), 2019 & 2024
Figure 32: Global: Ulcerative Colitis (Anti-Inflammatory Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 33: Global: Ulcerative Colitis (Anti-TNF Biologics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 34: Global: Ulcerative Colitis (Anti-TNF Biologics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 35: Global: Ulcerative Colitis (Immunosuppressant) Market: Sales Value (in Million USD), 2019 & 2024
Figure 36: Global: Ulcerative Colitis (Immunosuppressant) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 37: Global: Ulcerative Colitis (Calcineurin Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
Figure 38: Global: Ulcerative Colitis (Calcineurin Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 39: Global: Ulcerative Colitis (Other Drug Types) Market: Sales Value (in Million USD), 2019 & 2024
Figure 40: Global: Ulcerative Colitis (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 41: Global: Ulcerative Colitis (Oral) Market: Sales Value (in Million USD), 2019 & 2024
Figure 42: Global: Ulcerative Colitis (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 43: Global: Ulcerative Colitis (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
Figure 44: Global: Ulcerative Colitis (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 45: Global: Ulcerative Colitis (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 46: Global: Ulcerative Colitis (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 47: Global: Ulcerative Colitis (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 48: Global: Ulcerative Colitis (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 49: Global: Ulcerative Colitis (Drug Store) Market: Sales Value (in Million USD), 2019 & 2024
Figure 50: Global: Ulcerative Colitis (Drug Store) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 51: Global: Ulcerative Colitis (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
Figure 52: Global: Ulcerative Colitis (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 53: North America: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 54: North America: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 55: United States: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 56: United States: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 57: Canada: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 58: Canada: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 59: Asia-Pacific: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 60: Asia-Pacific: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 61: China: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 62: China: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 63: Japan: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 64: Japan: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 65: India: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 66: India: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 67: South Korea: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 68: South Korea: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 69: Australia: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 70: Australia: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 71: Indonesia: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 72: Indonesia: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 73: Others: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 74: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 75: Europe: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 76: Europe: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 77: Germany: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 78: Germany: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 79: France: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 80: France: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 81: United Kingdom: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 82: United Kingdom: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 83: Italy: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 84: Italy: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 85: Spain: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 86: Spain: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 87: Russia: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 88: Russia: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 89: Others: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 90: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 91: Latin America: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 92: Latin America: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 93: Brazil: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 94: Brazil: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 95: Mexico: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 96: Mexico: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 97: Others: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 98: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 99: Middle East and Africa: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
Figure 100: Middle East and Africa: Ulcerative Colitis Market: Breakup by Country (in %), 2024
Figure 101: Middle East and Africa: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 102: Global: Ulcerative Colitis Industry: SWOT Analysis
Figure 103: Global: Ulcerative Colitis Industry: Value Chain Analysis
Figure 104: Global: Ulcerative Colitis Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Ulcerative Colitis Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Ulcerative Colitis Market Forecast: Breakup by Type (in Million USD), 2025-2033
Table 3: Global: Ulcerative Colitis Market Forecast: Breakup by Disease Type (in Million USD), 2025-2033
Table 4: Global: Ulcerative Colitis Market Forecast: Breakup by Molecule Type (in Million USD), 2025-2033
Table 5: Global: Ulcerative Colitis Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
Table 6: Global: Ulcerative Colitis Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
Table 7: Global: Ulcerative Colitis Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
Table 8: Global: Ulcerative Colitis Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 9: Global: Ulcerative Colitis Market: Competitive Structure
Table 10: Global: Ulcerative Colitis Market: Key Players

Product Code: SR112025A5663

The global ulcerative colitis market size reached USD 8.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 12.5 Billion by 2033, exhibiting a growth rate (CAGR) of 4.82% during 2025-2033. The market is experiencing growth due to rising disease prevalence, advancements in medical treatments, and supportive government policies. Moreover, increasing global awareness regarding innovative therapies in developed and developing regions is further adding value to the market.

Ulcerative Colitis Market Analysis:

Major Market Drivers: The surging number of ulcerative colitis globally, and the awareness about the existence of inflammatory bowel diseases, stimulate the demand for innovative treatments and diagnostic methods among patients. In addition, technological progress, the expansion of biologics and the invention of new therapies intensify market development. The growing expenditure on healthcare in developed and developing countries also promotes market enlargement.

Key Market Trends: There is an increasing trend toward personalized medicine in treating ulcerative colitis, emphasizing customized therapeutic methods based on genetic, environmental, and phenotypic characteristics. Furthermore, the increased adoption of biologics and biosimilars for managing severe cases is significantly influencing the direction of the pharmaceutical industry in this market.

Geographical Trends: North America leads the ulcerative colitis market due to advanced healthcare facilities, high healthcare expenditure, and established pharmaceutical companies. However, Asia Pacific is anticipated to develop at a significant rate, given the increased health facilities, patient awareness, and medical tourism centering the region, such as China and India.

Competitive Landscape: Some of the major market players in the ulcerative colitis industry include Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. among many others.

Challenges and Opportunities: The primary challenge of the market is the high cost of treatment, which may create barriers to access in low-income countries, particularly when biologics are involved. Another factor is the labor-intensive and lengthy drug approval process, which could delay new treatments from entering the market. Despite its severity, the challenge can serve as a basis for opportunities. Developing cost-effective therapies and streamlining the approval process can become beneficial for businesses across the globe.

Ulcerative Colitis Market Trends:

Increasing Prevalence of Ulcerative Colitis

The growth in the prevalence of ulcerative colitis, as well as the spread of awareness about the existence of inflammatory bowel diseases, stimulates the demand for innovative treatments and diagnostic methods among patients. In addition, technological progress, the expansion of biologics, and the invention of new therapies intensify market development. The growing expenditure on healthcare in developed and developing countries also promotes market enlargement. According to the NATIONAL LIBRARY OF MEDICINE, ulcerative colitis has an incidence of 9 to 20 cases per 100,000 persons per year. Its prevalence is 156 to 291 cases per 100,000 persons per year.

Advancements in Medical Treatments

Medical treatment of ulcerative colitis has come a long way with the development of biologics and small-molecule drugs. The positive spirit brought about by this progress has created more favorable market-related factors. On the one hand, advances in diagnostic technologies and the development of new targeted treatment approaches have positively affected the market due to increased adoption driven by the development of more effective treatments. For instance, Pfizer Inc. in 2023 announced that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY(TM) (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC).

Government and Regulatory Support

Favorable government policies and increased healthcare spending significantly impact the ulcerative colitis market growth. With regulatory approvals facilitating the rapid market entry of new and effective drugs, patients gain access to advanced treatment options. Additionally, several governments have ramped up funding for research and development, encouraging pharmaceutical companies to invest in innovative therapies for ulcerative colitis, which further stimulates market growth.

Ulcerative Colitis Industry Segmentation:

Breakup by Type:

Mild UC
Moderate UC
Severe UC

Mild UC accounts for the majority of the market share

The mild ulcerative colitis segment dominates owing to the greater prevalence of mild cases compared to moderate and severe forms. Patients with mild UC generally experience fewer symptoms, which can typically be managed with oral medications, such as aminosalicylates. It benefits from numerous first-line treatment options that are less expensive and have fewer side effects, making them accessible and favored by patients and healthcare providers. The availability of effective and affordable treatments contributes significantly to the dominance of this segment in increasing the overall ulcerative colitis market demand. Mild ulcerative colitis is treated with mesalamine (5-aminosalicylic acid, 5-ASA) and other UC medications across all countries. As per the American College of Gastroenterology (ACG) treatment instruction, ulcerative colitis (UC) is categorized as mild in patients who have fewer than four (4) bowel movements per day, minimal bleeding, and no appreciable urgency or abdominal pain. In comparative studies of 2.4 g and 4.8 g daily doses of mesalamine, it was found that patients with mild disease will improve with 2.4 g and 4.8 g doses of mesalamine.

Breakup by Disease Type:

Ulcerative Proctitis
Proctosigmoiditis
Left-sided Colitis
Pancolitis or Universal Colitis
Fulminant Colitis

Ulcerative proctitis holds the largest share in the industry

Ulcerative proctitis is considered the mildest due to the inflammation being confined to the rectum. Patients usually experience such symptoms as rectal bleeding, urgency, and tenesmus. As per the study by Matthew Mutch, in Shackelford's Surgery of the Alimentary Tract, 2 Volume Set (Eighth Edition), 2019, patients with ulcerative pancolitis for more than 8 years are at higher risk of colorectal cancer, with the risk ranging from 0.5% to 1% per year. The localized nature of symptoms is why it is easier to treat the condition with medicines that require the closest interaction with the perished area rather than using more invasive and less patient-friendly systemic treatment. The focused treatment combines fewer systemic side effects, which is why patients prefer using suppositories or enemas as treatment. Facing better treatment opportunities, patients with ulcerative proctitis have a very good prognosis. Hence, the demand for quality treatments is growing.

Breakup by Molecule Type:

Small Molecules
Biologics

Biologics represents the leading market segment

Biologics represent the largest segment in the market. The key reasons for the popularity of this therapy type involve its high efficiency in reducing inflammation and achieving and maintaining remission in patients suffering from moderate to severe disease. These protein-containing drugs work by aiming at particular parts of the immune system that encourage developing inflammation in the body. The increasing demand for biologics is explained by the growing number of approvals and biosimilars, which will make these drugs more available and less costly. For illustration purposes, in March 2024, Johnson & Johnson unveiled the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration pursuing approval of TREMFYA(R) (guselkumab) to treat adult patients with moderately to severely active ulcerative colitis. It is supported by data from the Phase 3 QUASAR program evaluating the efficacy and safety of TREMFYA(R) to treat patients with moderately to severely active UC who had an inadequate response or intolerance to traditional therapy, prior biologics and/or JAK inhibitors.

Breakup by Drug Type:

Anti-Inflammatory Drugs
Anti-TNF Biologics
Immunosuppressant
Calcineurin Inhibitors
Others

Anti-TNF biologics exhibits a clear dominance in the market

The market is currently dominated by anti-TNF biologics, primarily due to their ability to control inflammation and sustain remission in patients with moderate-to-severe conditions. Anti-TNF biologics are accustomed to neutralizing the action of a protein in the body known as TNF that causes inflammation, making them a preferable option for patients who are not treated with monotherapy. In addition, the established success of anti-TNF biologics in patient quality of life would agree with these results, despite concerns about costs and side effects.

Breakup by Route of Administration:

Oral
Injectable

Injectable dominates the market

Injectable medications hold a prominent position in the ulcerative colitis market revenue, primarily due to their capacity to deliver treatments directly to the bloodstream, effectively bypassing the digestive system. This category includes biologics such as infliximab and adalimumab, which are particularly used for moderate to severe cases. The preference for injectables stems from their rapid action and high efficacy, especially beneficial for patients who do not respond to oral medications. Additionally, the less frequent dosing requirement compared to oral medications enhances the appeal of injectables, making them a popular choice in managing ulcerative colitis and contributing to their substantial market share. Top of FormFor instance, in 2023, the Food and Drug Administration (FDA) indicated that the subcutaneous administration of vedolizumab is an approvable maintenance therapy for moderate to severe ulcerative colitis following intravenous infusion. It is the only FDA-approved biologic in ulcerative colitis maintenance therapy that is based on IV and SC dose-approved medication.

Breakup by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Drug Store
Others

Hospital pharmacies are the predominant market segment

Hospital pharmacies constitute the largest segment in the ulcerative colitis market forecast. Their pivotal role in distributing treatments stems from their proximity to patient care settings and their responsibilities in administering and monitoring therapies. Hospitals are often the first to receive new drug approvals, positioning them as primary channels for distributing advanced therapeutics. This segment benefits from direct interactions with pharmaceutical manufacturers and often engages in price negotiations, which can significantly influence treatment accessibility and adoption rates among patients. For instance, the Apollo Hospital pharmacy business is about to touch 10,000 crore in revenue this year with 5,790 pharmacies, Apollo is the largest pharmacy chain, adding 400-500 stores each year.

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

North America leads the market, accounting for the largest ulcerative colitis market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America dominates the ulcerative colitis market on account of the high occurrence of the disorder, superior medical facilities, and extensive funding for R&D activities. The American and Canadian health systems ensure the substantial usage of progressive treatments, and private insurance plans and campaigns further enhance the consumer understanding of products. Companies in the pharmaceutical and biotech sectors accelerate the development of innovative treatment methods. They integrate the most successful ones into their treatment protocols at an early stage, advancing the market. At present, ulcerative colitis has an incidence of 9 to 20 cases per 100,000 persons per year and 156 to 291 cases per 100,000 persons per year as per National Institute of Health (NIH). Ulcerative colitis market recent opportunities include numerous key players collaborating to expand their market growth. For instance, Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceuticals Industries Ltd., and Sanofi collaborated to create and co-commercialize asset TEV'574, to treat Ulcerative Colitis and Crohn's Disease.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the keyword industry include Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Leading players in the ulcerative colitis market recent developments include the development of advanced biologics and small molecule therapies, improved drug delivery systems, and expansion into untapped markets. The leading players are also involved in strategic initiatives such as partnerships, mergers, acquisitions, and increasing investment in research and innovation to enhance treatment efficacies. These efforts are aimed at boosting market share and addressing the unmet needs in ulcerative colitis management. Besides this, Pfizer Inc. unveiled that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for VELSIPITY(TM) (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator. This medication is intended for the treatment of patients aged 16 and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biological agent.

Latest News:

November 2021: Bristol Myers Squibb received European Commission approval for Zeposia (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis.Top of Form

March 2024: AbbVie Inc., and Landos Biopharma Inc. unveiled that AbbVie entered into a definitive agreement that provides for the acquisition of Landos, a clinical-stage biopharmaceutical corporation keen on developing advanced novel oral therapeutics for individuals with autoimmune disorders.

Key Questions Answered in This Report

1.How big is the ulcerative colitis market?
2.What is the future outlook of ulcerative colitis market?
3.What are the key factors driving the ulcerative colitis market?
4.Which region accounts for the largest ulcerative colitis market share?
5.Which are the leading companies in the global ulcerative colitis market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Ulcerative Colitis Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Type

6.1 Mild UC
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Moderate UC
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Severe UC
- 6.3.1 Market Trends
- 6.3.2 Market Forecast

7 Market Breakup by Disease Type

7.1 Ulcerative Proctitis
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Proctosigmoiditis
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Left-sided Colitis
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Pancolitis or Universal Colitis
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Fulminant Colitis
- 7.5.1 Market Trends
- 7.5.2 Market Forecast

8 Market Breakup by Molecule Type

8.1 Small Molecules
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Biologics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast

9 Market Breakup by Drug Type

9.1 Anti-Inflammatory Drugs
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Anti-TNF Biologics
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Immunosuppressant
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
9.4 Calcineurin Inhibitors
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
9.5 Others
- 9.5.1 Market Trends
- 9.5.2 Market Forecast

10 Market Breakup by Route of Administration

10.1 Oral
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
10.2 Injectable
- 10.2.1 Market Trends
- 10.2.2 Market Forecast

11 Market Breakup by Distribution Channel

11.1 Hospital Pharmacies
- 11.1.1 Market Trends
- 11.1.2 Market Forecast
11.2 Retail Pharmacies
- 11.2.1 Market Trends
- 11.2.2 Market Forecast
11.3 Drug Store
- 11.3.1 Market Trends
- 11.3.2 Market Forecast
11.4 Others
- 11.4.1 Market Trends
- 11.4.2 Market Forecast

12 Market Breakup by Region

12.1 North America
- 12.1.1 United States
  - 12.1.1.1 Market Trends
  - 12.1.1.2 Market Forecast
- 12.1.2 Canada
  - 12.1.2.1 Market Trends
  - 12.1.2.2 Market Forecast
12.2 Asia-Pacific
- 12.2.1 China
  - 12.2.1.1 Market Trends
  - 12.2.1.2 Market Forecast
- 12.2.2 Japan
  - 12.2.2.1 Market Trends
  - 12.2.2.2 Market Forecast
- 12.2.3 India
  - 12.2.3.1 Market Trends
  - 12.2.3.2 Market Forecast
- 12.2.4 South Korea
  - 12.2.4.1 Market Trends
  - 12.2.4.2 Market Forecast
- 12.2.5 Australia
  - 12.2.5.1 Market Trends
  - 12.2.5.2 Market Forecast
- 12.2.6 Indonesia
  - 12.2.6.1 Market Trends
  - 12.2.6.2 Market Forecast
- 12.2.7 Others
  - 12.2.7.1 Market Trends
  - 12.2.7.2 Market Forecast
12.3 Europe
- 12.3.1 Germany
  - 12.3.1.1 Market Trends
  - 12.3.1.2 Market Forecast
- 12.3.2 France
  - 12.3.2.1 Market Trends
  - 12.3.2.2 Market Forecast
- 12.3.3 United Kingdom
  - 12.3.3.1 Market Trends
  - 12.3.3.2 Market Forecast
- 12.3.4 Italy
  - 12.3.4.1 Market Trends
  - 12.3.4.2 Market Forecast
- 12.3.5 Spain
  - 12.3.5.1 Market Trends
  - 12.3.5.2 Market Forecast
- 12.3.6 Russia
  - 12.3.6.1 Market Trends
  - 12.3.6.2 Market Forecast
- 12.3.7 Others
  - 12.3.7.1 Market Trends
  - 12.3.7.2 Market Forecast
12.4 Latin America
- 12.4.1 Brazil
  - 12.4.1.1 Market Trends
  - 12.4.1.2 Market Forecast
- 12.4.2 Mexico
  - 12.4.2.1 Market Trends
  - 12.4.2.2 Market Forecast
- 12.4.3 Others
  - 12.4.3.1 Market Trends
  - 12.4.3.2 Market Forecast
12.5 Middle East and Africa
- 12.5.1 Market Trends
- 12.5.2 Market Breakup by Country
- 12.5.3 Market Forecast

13 SWOT Analysis

13.1 Overview
13.2 Strengths
13.3 Weaknesses
13.4 Opportunities
13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

15.1 Overview
15.2 Bargaining Power of Buyers
15.3 Bargaining Power of Suppliers
15.4 Degree of Competition
15.5 Threat of New Entrants
15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

17.1 Market Structure
17.2 Key Players
17.3 Profiles of Key Players
- 17.3.1 Abbott Laboratories
  - 17.3.1.1 Company Overview
  - 17.3.1.2 Product Portfolio
  - 17.3.1.3 Financials
  - 17.3.1.4 SWOT Analysis
- 17.3.2 AbbVie Inc.
  - 17.3.2.1 Company Overview
  - 17.3.2.2 Product Portfolio
  - 17.3.2.3 Financials
  - 17.3.2.4 SWOT Analysis
- 17.3.3 AstraZeneca plc
  - 17.3.3.1 Company Overview
  - 17.3.3.2 Product Portfolio
  - 17.3.3.3 Financials
  - 17.3.3.4 SWOT Analysis
- 17.3.4 Bristol-Myers Squibb Company
  - 17.3.4.1 Company Overview
  - 17.3.4.2 Product Portfolio
  - 17.3.4.3 Financials
  - 17.3.4.4 SWOT Analysis
- 17.3.5 Eli Lilly and Company
  - 17.3.5.1 Company Overview
  - 17.3.5.2 Product Portfolio
  - 17.3.5.3 Financials
  - 17.3.5.4 SWOT Analysis
- 17.3.6 F. Hoffmann-La Roche Ltd.
  - 17.3.6.1 Company Overview
  - 17.3.6.2 Product Portfolio
  - 17.3.6.3 Financials
- 17.3.7 GlaxoSmithKline plc
  - 17.3.7.1 Company Overview
  - 17.3.7.2 Product Portfolio
  - 17.3.7.3 Financials
  - 17.3.7.4 SWOT Analysis
- 17.3.8 Johnson & Johnson
  - 17.3.8.1 Company Overview
  - 17.3.8.2 Product Portfolio
  - 17.3.8.3 Financials
  - 17.3.8.4 SWOT Analysis
- 17.3.9 Merck & Co. Inc.
  - 17.3.9.1 Company Overview
  - 17.3.9.2 Product Portfolio
  - 17.3.9.3 Financials
  - 17.3.9.4 SWOT Analysis
- 17.3.10 Pfizer Inc.
  - 17.3.10.1 Company Overview
  - 17.3.10.2 Product Portfolio
  - 17.3.10.3 Financials
  - 17.3.10.4 SWOT Analysis
- 17.3.11 Takeda Pharmaceutical Company Limited
  - 17.3.11.1 Company Overview
  - 17.3.11.2 Product Portfolio
  - 17.3.11.3 Financials
  - 17.3.11.4 SWOT Analysis
- 17.3.12 Teva Pharmaceutical Industries Ltd.
  - 17.3.12.1 Company Overview
  - 17.3.12.2 Product Portfolio
  - 17.3.12.3 Financials
  - 17.3.12.4 SWOT Analysis

潰瘍性大腸炎市場レポート：タイプ別、疾患タイプ別、分子タイプ別、薬剤タイプ別、投与経路別、流通チャネル別、地域別、2025年～2033年

Ulcerative Colitis Market Report by Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033

潰瘍性大腸炎の市場分析：

潰瘍性大腸炎の市場の動向：

目次

第1章 序文

第2章 調査範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の潰瘍性大腸炎市場

第6章 市場内訳：タイプ別

第7章 市場内訳：疾患タイプ別

第8章 市場内訳：分子タイプ別

第9章 市場内訳：薬剤タイプ別

第10章 市場内訳：投与経路別

第11章 市場内訳：流通チャネル別

第12章 市場内訳：地域別

第13章 SWOT分析

第14章 バリューチェーン分析

第15章 ポーターのファイブフォース分析

第16章 価格分析

第17章 競合情勢